PERIOPERATIVE heart rate control with ␤-adrenoreceptor blockers (␤-blockers) to prevent myocardial ischemia and infarction after noncardiac surgery is recommended in the 2007 American College of Cardiology/American Heart Association Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. 1 These class II recommendations were largely based on two small trials, one of which enrolled very high-risk patients with multiple cardiovascular risk factors, and the methodology of the other has been the subject of discussion. 2, 3 In contrast, several larger-sized trials failed to demonstrate benefit of perioperative ␤-blockade in terms of a reduced incidence of myocardial infarction. 4 -7 Moreover, the recently published PeriOperative Ischemic Evaluation Study (8,351 patients) found that ␤-blockers reduced postoperative myocardial infarction, but at the cost of an increased stroke and mortality rate. 8 Untoward adverse events from ␤-blockers are of particular concern among lower-risk patients who contribute nearly 90% of the perioperative deaths but in whom the benefit of therapy has been questioned. Evaluation of a large administrative data set identified that patients with one or fewer cardiac risk factors showed no improvement in outcome (death) associated with ␤-blockade. 9 Although this study was designed carefully, its results must be interpreted with caution as the timing of ␤-blocker prescription and outcome could not be determined in the administrative database used. It is possible that the association between ␤-blockade and adverse outcomes resulted from appropriate prescriptions of ␤-blockers to patients who had suffered an adverse event (confounding by indication) rather than a failure of prophylaxis.
We performed this study to estimate the impact of perioperative ␤-blocker prescription on the occurrence of postopereative myocardial infarction (POMI) in a large cohort of low-risk patients undergoing joint arthroplasty in whom the timing of both ␤-blocker prescription and adverse events could be determined.
Materials and Methods

Patients
After approval of the local Research Ethics Board (The Ottawa Hospital, Ottawa, Ontario, Canada), all patients undergoing elective hip or knee arthroplasty at The Ottawa Hospital between January 1, 2002 and June 30, 2006 were identified. The Ethics Board waived the need for written informed consent, as data were retrospective and anonymous. The Ottawa Hospital is a regional referral center and teaching hospital that provides approximately 1,400 hip and knee replacements annually. No restrictions on perioperative care were imposed during the time period in question. Patient fitness for surgery was assessed by an anesthesiologist in the Preoperative Assessment Unit, and preoperative testing was indicated by institutional guidelines. Patients felt to be at increased risk of perioperative complications could be referred for preoperative investigation and treatment at the discretion of the anesthesiologist performing the preoperative evaluation. Choice of intraoperative anesthetic and surgical technique was made by the attending anesthesiologist and surgeon, respectively. Daily postoperative care was provided by the orthopedic surgeons.
Data
All data were obtained from The Ottawa Hospital Data Warehouse, a peer-reviewed research infrastructure established to facilitate health services research. The Ottawa Hospital Data Warehouse integrates clinical data from laboratory, pharmacy, and radiology information systems with administrative data from patient registration and health records systems. Patients in the Ottawa Hospital Data Warehouse were identified by using encrypted unique identifiers. The linking of appropriate tables and the recoding of important variables of interest was performed by an experienced programmer and overseen by a health services researcher whose primary focus is the use of healthcare databases (Alan J. Forster, M.D., Ph.D., General Internist and Associate Professor, Department Internal Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada).
Patient gender, age, type of surgery, and the occurrence of death during admission were obtained from the patient registration system. Details regarding the dates and type of the ␤-blocker prescribed were identified by using pharmacy data. Troponin T, hemoglobin, and creatinine values were selected from laboratory data. Preexisting comorbid conditions were identified by using diagnostic codes in the discharge abstracts, except for chronic renal failure, which was defined as a preoperative creatinine value greater than 2 mg · dl
Ϫ1
.
Perioperative ␤-blockade
The exposure of interest was the prescription of any ␤-blocker in the perioperative period. In most prospective trials, perioperative ␤-blockade was initiated on admission (the day before surgery) or at the day of surgery (postoperative day [POD] 0) and continued for at least 1 week or until discharge, but in two trials for up to 30 days after surgery. [2] [3] [4] [5] [6] 8 In the current study, however, pharmacy data could not distinguish between prescriptions for chronic preoperative ␤-blocker treatment for hypertension or angina and those initiated prophylactically on admission. Furthermore, ␤-blockers ordered after the day of surgery may have been prescribed for the treatment of an ongoing adverse postoperative event and could not, for the purposes of this study, be considered a prophylactic risk reduction strategy. Therefore, patients were divided into three ␤-blocker exposure groups: those prescribed a ␤-blocker at any time on POD0 in whom prescription was continued for at least 7 days thereafter (or until hospital discharge, whichever came first), those prescribed a ␤-blocker on POD0 but in whom prescription was discontinued at any time during the first 7 days of surgery, and those not prescribed a ␤-blocker on POD0.
Outcome
The primary outcome of interest, POMI, was defined by a Troponin T value greater than 0.1 ng · ml Ϫ1 (highest value). POMI occurring between POD1 and POD10 were included. Coding of pharmacy data precluded the determination of the temporal relationship between exposure (␤-blocker) and outcome (POMI) in units of time less than a calendar day. It was likely that a POMI on the day of surgery would prompt a postevent prescription for ␤-blocker leading to "confounding by indication." POMI occurring more than 10 days after surgery (POD10) could not be reliably recorded or linked to the surgical procedure in our inpatient data set. Death from all causes occurring from POD1 to POD10 was considered as a secondary outcome. Analysis SPSS 15.0 (SPSS inc., Chicago, IL) was used for statistical analysis. Baseline characteristics of all patients were described as proportions or mean Ϯ SD as appropriate. Multivariable logistic regression was used to calculate the predicted probability of an individual being prescribed a ␤-blocker on admission (propensity score). As a Troponin was measured selectively in patients suspected of experiencing a POMI and/or myocardial ischemia, the propensity score included whether or not a Troponin was measured postoperatively. Patients prescribed a ␤-blocker might be perceived by their attending physicians to be at higher risk, resulting in a greater likelihood of having a Troponin level drawn. A greater frequency of Troponin assay may in turn increase detection of silent POMI in those patients who were on a ␤-blocker.
Two separate multivariable logistic regression models were subsequently used to determine the association between the ␤-blockade and outcome. In the first model, the likelihood of ␤-blockade (propensity score) and perioperative variables, including type of procedure and preoperative as well as postoperative hemoglobin level, were used to evaluate the relationship between ␤-blockade and outcome. In the second model the individual predictors form the Revised Cardiac Risk Index (RCRI) 10 were used to adjust the relationship between ␤-blockade and POMI for known correlates of postoperative cardiac morbidity. To facilitate interpretation, the association between ␤-blockade prescription status and outcome was stratified by using the four classes of the RCRI and postoperative hemoglobin level. Similar analyses were conducted to evaluate the association between ␤-blockade and all-cause mortality. The associations between ␤-blockade and the outcomes of interest were expressed as odds ratios (OR) or mean differences with 95% confidence interval (CI).
Results
In total 5,178 patient records were available, but 20 patients were excluded because they experienced a POMI on POD0 or after POD10 ( fig. 1) . A ␤-blocker was prescribed on POD0 to 992 (19%) of the remaining 5,158 patients. This ␤-blocker was discontinued within 7 days of surgery in 252 (25%) of these 992 patients ( fig.  1 ). Patients who were prescribed a ␤-blocker were older and were more likely to have significant comorbidities (table 1) . The factors associated with POMI and potentially related to prescription of a ␤-blocker on POD0 are described in table 2.
Of the 5,158 patients, 77 (1.5%) had a POMI between POD1 and POD10 ( fig. 1 ), and 54 (1.0%) died within that interval. The event rate of POMI during the first 10 postoperative days was 3.0% (n ϭ 22) in those who were prescribed a ␤-blocker during at least 7 days or until hospital discharge, 7.9% (n ϭ 20) in those in whom the ␤-blocker prescription was discontinued during the first week, and 0.8% (n ϭ 35) in patients who were not prescribed a ␤-blocker on POD0. Most events occurred Data expressed as number (%) unless otherwise specified.
␤-blocker ϭ those patients prescribed a ␤-blocker on the day of surgery; SD ϭ standard deviation.
during the first 5 days after surgery ( fig. 2 ). Patients on a ␤-blocker had a longer hospital stay (table 1) . Age, comorbidity, ␤-blocker prescription, preoperative, and postoperative hemoglobins Ͻ 100 g · l Ϫ1 and total knee arthroplasty were significantly associated with POMI (table 2) . Patients in whom ␤-blocker prescription was discontinued during the first week had a much higher risk for POMI (OR 10, 95% CI 5.8 -18). Increasing cardiovascular risk, as defined by RCRI, was also associated with increased risk of POMI. ␤-blockers of relatively short and long durations of action had comparable effects on the occurrence of POMI. A propensity score predicting the probability of a patient being prescribed a ␤-blocker on POD0 was calculated. The area under the receiver operator characteristic curve of the propensity score model was 0.71 (95% CI 0.69 -0.73) (table 3). The propensity score for prescription of a ␤-blocker on POD0 was subdivided into quintiles to enhance interpretation of this propensity score when it was used to risk-adjust the association between 
Fig. 2. Kaplan-Meier curve showing the cumulative event-free
proportion (a myocardial infarction did not occur) during the first 10 postoperative days. The solid line represents patients who were not prescribed a ␤-blocker on the day of surgery (cumulative event rate 0.8%). The dashed line represents those patients who were prescribed a ␤-blocker on the day of surgery and in whom this prescription was continued for at least 1 week or until hospital discharge, whichever came first (cumulative event rate 3.0%). The dashed -dotted line represents those who were prescribed a ␤-blocker on the day of surgery and in whom this prescription was discontinued during the first week after surgery (cumulative event rate 7.9%). The factors reported in this table were used to calculate a propensity score that was used to risk-adjust the association between ␤-blockade and perioperative myocardial infarction. The area under the receiver operating characteristic curve of this propensity score was 0.71 (95% CI 0.69-0.73).
CI ϭ confidence interval.
␤-blocker prescription and outcomes (table 4)
. Discontinuation of ␤-blocker prescription during the first week was significantly associated with POMI (table 4) , whereas continuation was not. For every decrease in postoperative hemoglobin with 10 g · l Ϫ1 , the risk of POMI increased by 50% (OR 1.5, 95% CI 1.2-1.8). Adjustment for confounding factors included in the RCRI instead of using the propensity scores yielded comparable results (table 5). The area under the receiver operator characteristic curve of the RCRI predicting POMI was 0.77 (95% CI 0.70 -0.83).
Discontinuation of ␤-blocker prescription was associated with death (OR 2.0, 95% CI 1.0 -3.9), but continuation showed a nonsignificant trend to improvement (OR 0.5, 95% CI 0.2-1.2) (fig. 3 ). Other variables significantly associated to death were knee replacement (OR 0.2, 95% CI 0.1-0.6) and the propensity score (model not shown). Figure 4 graphically shows the incidence of POMI stratified across RCRI class, ␤-blocker prescription status, and postoperative hemoglobin. In both postoperative hemoglobin categories ( fig. 4A postoperative hemoglobin greater than 100 g · l Ϫ1 and fig. 4B postoperative hemoglobin less than 100 g · l Ϫ1 ), discontinuation of ␤-blocker prescription was associated with an increased risk of POMI, especially in lower-risk patients (RCRI I and II).
Finally, a comparable regression analysis including all POMI (i.e., including those occurring on POD0 and after POD10) was conducted. This analysis did not change the direction of our findings.
Discussion
The results of this observational study indicate that discontinuation of ␤-blocker prescription during the first week after surgery in patients undergoing hip and knee arthroplasty was significantly associated with POMI (OR 2.0, 95% CI 1.1-3.9) and death (OR 2.0, 95% CI 1.0 -3.9). A lower postoperative hemoglobin level independently contributed to this risk. The association between The dashed -dotted line represents those who were prescribed a ␤-blocker on the day of surgery and in whom this prescription was discontinued during the first week after surgery (cumulative event rate 7.5%).
␤-blocker discontinuation and POMI persisted after adjustment for factors predicting the use of a ␤-blocker and risk factors known to predict adverse cardiac events. Our results showed a significant association with POMI and mortality in those patients in whom ␤-blocker prescription was discontinued. These results seem to support and might explain Lindenauer's findings that use of ␤-blockers in low-risk populations did not yield an improvement in perioperative mortality. 9 In this study of more than 650,000 patients undergoing elective noncardiac surgery, more than 120,000 (18%) received a ␤-blocker during the first two postoperative days. The vast majority (86%) of the patients in this large administrative data set had no more than one cardiac risk factor (RCRI class I and II). Among these patients at low cardiovascular risk, ␤-blocker treatment was associated with no benefit and possible harm with an OR for mortality of 1.4 (95% CI 1.3-1.6) and 1.1 (95% CI 1.0 -1.3) in patients classified as RCRI I and II, respectively. A reduction in mortality with ␤-blockade was noted only among the minority (2.6%) of patients with at least three cardiac risk factors. However, although this was a carefully designed study, its results must be interpreted with caution because the timing of ␤-blocker prescription and outcome could not be determined in the administrative database used.
Some remarks about the three perioperative ␤-blocker groups should be made. First, in the group in which ␤-blocker prescription was discontinued, the reasons for discontinuation were not known, and these patients had higher baseline risk for the occurrence of the outcome (table 1) . Cessation of ␤-blocker prescription could be in response to an acute event that preceded POMI or death. Furthermore, the group that was never prescribed a ␤-blocker (our control group) may have included patients who were on a ␤-blocker at home but in whom a ␤-blocker was not started on admission. In fact, such patients were withdrawn, which may have increased the number of events in the control group, resulting in a weakening of the association between discontinuation .
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of ␤-blocker prescription and POMI (i.e., the reported OR of 2.0 is underestimated). Finally, a ␤-blocker prescribed on the day of surgery and afterwards for at least 1 week seemed to fail to improve outcomes in low-risk patients (RCRI class I and II) (table 4) . It should be noted, however, that we were not able to distinguish between patients who were on chronic ␤-blockade and those who were prescribed ␤-blockers perioperatively, which is an important limitation. Although multivariable regression techniques were used to adjust for factors associated with ␤-blocker prescription and conditions known to be associated with postoperative cardiac morbidity, it remains possible that ␤-blockade represents a surrogate for risk factors not assessed or adjusted for in our models. On the other hand, results from randomized trials of perioperative ␤-blockade do suggest that lowerrisk populations may not benefit from prophylaxis. Two trials of perioperative ␤-blockade, the Diabetic Postoperative Mortality and Morbidity 4 and Metoprolol after Vascular Surgery 5 trials, recruited patients from relatively unselected groups of patients perceived to be at risk of perioperative cardiac events. The Diabetic Postoperative Mortality and Morbidity trial enrolled 961 patients with a single cardiac risk factor (diabetes mellitus) and found no reduction in risk with perioperative metoprolol therapy (hazard ratio 1.1; 95% CI 0.8 -1.4). 4 Similarly, metoprolol prophylaxis failed to significantly reduce the relative risk of cardiac events (relative risk reduction 15%; 95% CI -38% to 48%) in a population of 494 patients undergoing vascular surgery in whom 297 (60%) had only a single risk factor. 5 In contrast, the large-sized Perioperative Ischemic Evaluation Study included intermediate risk patients and found significant reductions in perioperative cardiac morbidity in all RCRI subgroups of patients, but at the cost of an increased overall mortality and stroke rate. 8 It should be mentioned that the dosing of metoprolol in this trial was higher than the generally recommended starting dose of metoprolol.
11,12 It might be argued that this high dose contributed to the increased incidence of side effects (mortality and stroke). However, a recent meta-analysis showed that the incidence of cerebrovascular accidents and hypotension was uniform in all studies included. 13 considered to be at low to intermediate risk of cardiac death and nonfatal myocardial infarction. 1, 18 As a result of their advanced age and poor functional capacity, patients awaiting joint replacement represent a relatively large group of patients in whom the perioperative use of ␤-blockers may be considered. However, before initiating ␤-blocker prophylaxis, both the risks of perioperative cardiac events and the risks and benefit of ␤-blockade should be taken into account. To date, there still have been relatively few patients enrolled in trials of perioperative ␤-blockade. A systematic review that included Perioperative Ischemic Evaluation Study results identified slightly more than 10,000 subjects suffering 295 all-cause deaths and 434 nonfatal POMI in randomized trials of ␤-blockers in noncardiac surgery. 8 A more recently published meta-analysis including 12,306 patients from 33 trials reported a decrease in the incidence of nonfatal myocardial infarction and myocardial ischemia at the expense of an increase in nonfatal strokes. 13 It concluded that evidence does not support the use of ␤-blocker therapy for the prevention of perioperative clinical outcomes in patients having noncardiac surgery. It should be noted, however, that about 70% of the patients included in this meta-analysis were form the Perioperative Ischemic Evaluation Study.
Most foregoing trials have focused on higher risk patients, leaving the question of risk reduction in low-risk populations unanswered. The results of the current study identified that nearly 78% of POMIs occurred in patients with no more than one cardiac risk factor (RCRI I and II), suggesting that efforts to reduce the incidence of POMI should not be limited to high-risk patients. Our results confirm the American College of Cardiology/American Heart Association Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery, which recommend not to withdraw ␤-blocker therapy. 
